Thursday, February 12, 2026
Biogen names Dr. Maria C. Freire as next board chair
Biogen has announced a leadership change at the top of its Board of Directors. The board has elected Dr. Maria C. Freire as Chair, effective immediately following Biogen’s 2026 Annual Meeting of Stockholders, scheduled for June 9, 2026.
Current Chair Caroline Dorsa will retire from the board and will not stand for re-election at the Annual Meeting. Dorsa has served on Biogen’s board for 16 years.
Freire has served as a director since 2021
Freire joined Biogen’s board in 2021. She serves on the Corporate Governance Committee and on the Compensation and Management Development Committee. Biogen President and CEO Christopher A. Viehbacher thanked Dorsa for her contributions and said Freire brings broad expertise in science and drug development.
Career spans biomedical innovation and public-private partnerships
Biogen said Freire brings experience across biomedical innovation, drug development, public-private partnerships, and science policy. She is Founder and Principal of The Freire Group, a strategic advisory firm for life sciences organizations. In addition to Biogen, she serves on the boards of Alexandria Real Estate Equities, Exelixis and Keystone Symposia, and she is a member of the National Academy of Medicine and the Council on Foreign Relations.
Previously, Freire led the Foundation for the National Institutes of Health (FNIH), overseeing large-scale collaborations spanning areas such as oncology, neurodegeneration, autoimmune disorders and infectious diseases. Earlier in her career, she served as President and CEO of the TB Alliance, where she helped advance pretomanid into clinical trials. Pretomanid is now approved for treating multidrug-resistant tuberculosis. Additional roles included President of the Albert and Mary Lasker Foundation and Director of the NIH Office of Technology Transfer.
Pipeline outlook referenced
In her statement, Freire pointed to several upcoming readouts over the next 18 months and mentioned potentially filing-enabling work in lupus and nephrology.
Related articles
Sanofi appoints Belén Garijo as new CEO
Sanofi has appointed Belén Garijo as CEO. Paul Hudson will leave on Feb. 17, 2026, with Olivier Charmeil serving as interim leader.
Engelhard strengthens strategic development with new CCSO role
Engelhard has created a Transformation Office and appointed Ann-Katrin Frank as Chief Commercial Strategy Officer to steer strategic development.
Daiichi Sankyo Appoints New Leadership for European Research Center
Daiichi Sankyo has appointed Dr. Veronika Rozehnal as the new Head of the Translational Research Center Europe. She succeeds Dr. Jürgen Müller, who is retiring after nearly 30 years of research service.
New employee representative on the Board of Directors of Novo Nordisk
After 22 years at Novo Nordisk, Thomas Rantzau steps down from the Board of Directors. His former alternate, Tanja Villumsen, assumes the role of employee representative with immediate effect.
Benjamin Hein Appointed Member of the Executive Board and CEO Electronics at Merck
Merck has appointed Benjamin Hein as a member of the Executive Board and CEO Electronics. The experienced executive will assume the role on May 1, 2026, succeeding Kai Beckmann.
Jonas Gehrling joins the management team of Serviceplan Content Health
As of January 1, 2026, Jonas Gehrling has joined the management team of Serviceplan Content Health. Together with Nadine van Maanen, he will lead the Berlin-based healthcare content agency.
Leadership Transition at Psyma+Exevia
Psyma+Exevia Health GmbH sets the course for the future: Heidi Lüttgens assumes management responsibility from Roland Herterich and Norbert Schell. The leadership transition combines continuity with new momentum for growth and innovation.
Florian Truckenbrodt takes over Sales and Marketing
As of February 1, 2026, Alliance Healthcare Germany will bundle Sales and Marketing under one leadership. Florian Truckenbrodt will be responsible for both areas to further strengthen pharmacies in the market.